There were 1,825 press releases posted in the last 24 hours and 442,414 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image